Applied Therapeutics, Inc.

Quick facts

Phase 3 pipeline

• AT-007 · Endocrinology / Diabetes
  AT-007 is a small molecule that inhibits aldose reductase, the first enzyme in the polyol pathway, to reduce sorbitol accumulation and prevent diabetic complications.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Applied Therapeutics, Inc. portfolio CI brief
• Applied Therapeutics, Inc. pipeline updates RSS